For more than 20 years, Dr. Burt Adelman has played prominent roles at some of the Boston area’s most successful biopharmaceutical companies. Most recently, Dr. Adelman served as executive vice president of research and development for Dyax (acquired by Shire for $6.5 billion in 2015). Previously, he held a number of executive leadership roles at Biogen, including executive vice president of research and development and executive vice president for portfolio strategy, leading development efforts for Angiomax (anticoagulation), Avonex (multiple scleroris), Amevive (psoriasis) and Tysabri (multiple sclerosis). He serves on the board of directors of Catabasis Pharmaceuticals.